Clinical Trials Browser

INDUSTRY × Has results × Smoldering Multiple Myeloma × Clear all

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT01441973 2018-01-23

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Phase 2 Completed

41 enrolled 17 charts

Smoldering Multiple Myeloma

NCT01222286 2014-05-09

KIRMONO

Phase 2 Completed

30 enrolled 10 charts

Smoldering Multiple Myeloma